Milran Tablet 12.5 mg
Milran Tablet 12.5 mg Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | Milran Tablet 12.5 mg |
| Generic | Milnacipran Hydrochloride |
| Weight | 12.5 mg |
| Type | Tablet |
| Therapeutic Class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Manufacturer | Beacon Pharmaceuticals PLC |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
Milnacipran is indicated for the management of fibromyalgia. Milnacipran is not approved for use in pediatric patientsDosage
Milran Tablet 12.5 mg dosage
The recommended dose of Milnacipranis 100 mg/day (50 mg twice daily). Based on efficacy and tolerability dosing may be titrated according to the following schedule:Day 1:12.5 mg onceDays 2-3:25 mg/day (12.5 mg twice daily)Days 4-7:50 mg/day (25 mg twice daily)After Day 7:100 mg/day (50 mg twice daily)Based on individual patient response, the dose may be increased to 200 mg/day (100 mg twice daily). Doses above 200 mg/day have not been studied. Should be taken with food. Preferably taken during meals.Side Effects
Increased heart rate, HTN, increased liver enzymes, severe liver injury, hyponatraemia, abnormal bleeding, dysuria, mydriasis, nausea, vomiting, constipation, headache, insomnia, dizziness, hot flushes, hyperhidrosis, palpitations, dry mouth, migraine.Precaution
Patient with major depressive disorder or other psychiatric disorders, history of dysuria, controlled narrow-angle glaucoma, pre-existing HTN, tachyarrhythmias or other CV disease, history of seizure disorder or condition predisposing to seizures (e.g. brain damage, alcoholism). Avoid abrupt withdrawal. Severe hepatic and moderate to severe renal impairment including ESRD. Pregnancy and lactation.Interaction
Increased risk of bleeding with aspirin, NSAIDs, warfarin and other drugs that affect coagulation. Increased CNS effects with centrally-acting drugs (e.g. clomipramine). Increased risk of serotonin syndrome and NMS-like reactions with serotonergic drugs (e.g. tramadol), SSRIs, other selective serotonin-norepinephrine reuptake inhibitors, 5-HT1 receptor agonists (e.g. sumatriptan), antipsychotic agents and other dopamine antagonists. May inhibit antihypertensive effect of clonidine. May potentiate adverse haemodynamic effects with digoxin. Paroxysmal HTN and cardiac arrhythmia may occur when taken concurrently with epinephrine or norepinephrine.Pregnancy & Breastfeeding use
Pregnancy: Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during Milnacipran therapy. Patients should be encouraged to enroll in the Milnacipran Pregnancy Registry if they become pregnant, preferably before any prenatal testing is done. This registry is collecting information about the safety of milnacipran during pregnancy. Nursing: Advise patients to notify their physician if they are breast feedingContraindication
Uncontrolled narrow-angle glaucoma. Concomitant use with MAOI or within 2 wk after withdrawal of MAOI.Special Warning
Renal Impairment: Severe (CrCl 5-29 mL/min): 25 mg bid, may increase to 50 mg bid according to response. End stage renal disease (ESRD): Not recommended.Pediatric use: Safety and effectiveness of Milnacipran in a fibromyalgia pediatric population below the age of 18 have not been established. The use of Milnacipran is not recommended in pediatric patients.Acute Overdose
Symptoms: Increased BP, cardio-resp arrest, changes in the level of consciousness (ranging from somnolence to coma), confusional state, dizziness, and increased hepatic enzymes. Management: Symptomatic treatment with gastric lavage and activated charcoal. Maintain adequate airway, oxygenation and ventilation and monitor cardiac rhythm and vital signs. May give cyproheptadine with adequate temp control to treat serotonin syndrome.Storage Condition
Store at 25° C.Innovators Monograph
You find simplified version here Milran Tablet 12.5 mg
